

## AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous versions, and listings, of claims in this application.

### Listing of Claims

1. **(Previously presented)** An oligopeptide having the amino acid sequence:  
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
2. **(Previously presented)** The oligopeptide according to Claim 1 wherein one or more of the amino acids of said oligopeptide are D isomers.
3. **(Previously presented)** The oligopeptide according to Claim 2, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
4. **(Previously presented)** The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is amidated.
5. **(Previously presented)** The oligopeptide according to Claim 1, wherein said oligopeptide is in salt form.
6. **(Previously presented)** The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
7. **(Original)** An oligopeptide having the structural formula:  
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH<sub>2</sub>.
8. **(Previously presented)** An oligopeptide according to Claim 7, where said oligopeptide is in salt form.
- 9-10. **(Canceled)**
11. **(Previously presented)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is amidated.

12. **(Previously presented)** The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is amidated.

13. **(Previously presented)** The oligopeptide according to Claim 2, wherein said oligopeptide is in salt form.

14. **(Previously presented)** The oligopeptide according to Claim 3, wherein said oligopeptide is in salt form.

15. **(Previously presented)** The oligopeptide according to Claim 4, wherein said oligopeptide is in salt form.

16 - 17. **(Canceled)**

18. **(Previously presented)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

19. **(Previously presented)** The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

20. **(Previously presented)** The oligopeptide according to Claim 4, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

21. **(Previously presented)** The oligopeptide according to Claim 5, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

22-28. **(Canceled)**

29. **(Currently Amended)** A pharmaceutical composition comprising an oligopeptide ~~according to any one of Claims 11 to 28~~ as in any of Claims 1-8 or 11-15 or 18-21, further comprising and a pharmaceutically acceptable medium.

Serial No. 10/780,321

Filing Date: February 17, 2004

30. **(Previously presented)** The pharmaceutical composition according to Claim 29, wherein said pharmaceutically acceptable medium comprises an excipient.

31. **(Previously presented)** The pharmaceutical composition according to Claim 30, wherein said excipient comprises mannitol.